The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

By Horio Akiyo  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite

Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers

By Kollara A.  

Breast Cancer Research and Treatment, Vol. 67, Iss. 3, 2001-06 ,pp. : 245-253

Springer Publishing Company

Access to resources Recommend Favorite

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

By Lobbezoo Dorien   Kampen Roel   Voogd Adri   Dercksen M.   den Berkmortel Franchette   Smilde Tineke   Wouw Agnes   Peters Frank   Riel Johanna   Peters Natascha   Boer Maaike   Borm George   Tjan-Heijnen Vivianne  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 507-514

Springer Publishing Company

Access to resources Recommend Favorite

HER2-Positive Breast Cancer: Incidence, Prognosis, and Treatment Options

By Estévez L.G.  

American Journal of Cancer, Vol. 2, Iss. 3, 2003-01 ,pp. : 169-179

Adis International

Access to resources Recommend Favorite